ATXI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATXI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Avenue Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil. Avenue Therapeutics's Average Total Inventories for the quarter that ended in Mar. 2024 was $0.00 Mil.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
The historical data trend for Avenue Therapeutics's Inventory Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avenue Therapeutics Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Inventory Turnover | Get a 7-Day Free Trial | - | - | - | - | - |
Avenue Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Inventory Turnover | Get a 7-Day Free Trial | - | - | - | - | - |
Avenue Therapeutics's Inventory Turnover for the fiscal year that ended in Dec. 2023 is calculated as
Inventory Turnover (A: Dec. 2023 ) | |||||||
= | Cost of Goods Sold | / | Average Total Inventories | ||||
= | Cost of Goods Sold (A: Dec. 2023 ) | / ( | (Total Inventories (A: Dec. 2022 ) | + | Total Inventories (A: Dec. 2023 )) | / | count ) |
= | 0 | / ( | (0 | + | 0) | / | 1 ) |
= | 0 | / | 0 | ||||
= | N/A |
Avenue Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as
Inventory Turnover (Q: Mar. 2024 ) | |||||||
= | Cost of Goods Sold | / | Average Total Inventories | ||||
= | Cost of Goods Sold (Q: Mar. 2024 ) | / ( | (Total Inventories (Q: Dec. 2023 ) | + | Total Inventories (Q: Mar. 2024 )) | / | count ) |
= | 0 | / ( | (0 | + | 0) | / | 1 ) |
= | 0 | / | 0 | ||||
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avenue Therapeutics (NAS:ATXI) Inventory Turnover Explanation
Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Avenue Therapeutics's Days Inventory for the three months ended in Mar. 2024 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Mar. 2024 ) | / | Cost of Goods Sold (Q: Mar. 2024 ) | * | Days in Period |
= | 0 | / | 0 | * | 365 / 4 | |
= |
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Avenue Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Mar. 2024 ) | / | Revenue (Q: Mar. 2024 ) |
= | 0 | / | 0 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.
Thank you for viewing the detailed overview of Avenue Therapeutics's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Rosenwald Lindsay A Md | director | 375 PARK AVE, NEW YORK NY 10152 |
Fortress Biotech, Inc. | 10 percent owner | 1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154 |
Invagen Pharmaceuticals, Inc. | 10 percent owner | SITE B, 7 OSER AVE., HAUPPAUGE NY 11788 |
Alexandra Maclean | officer: Chief Executive Officer | C/O AVENUE THERAPEUTICS, INC., 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NC 10014 |
Faith L. Charles | director | ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019 |
David Jin | officer: Int. PEO, Int. PFO, and COO | C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036 |
Joseph Walter Vazzano | officer: Chief Financial Officer | 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019 |
Neil Herskowitz | director | 2109 BROADWAY, SUITE 206, NEW YORK NY 10023 |
Curtis Gale Oltmans | director | C/O ARRAY BIOPHARMA INC., 3200 WALNUT ST., BOULDER CO 80301 |
Jay D Kranzler | director | 4350 EXECUTIVE DRIVE, SUITE 325, SAN DIEGO CA 92121 |
Lucy Lu | director, officer: President, CEO | THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137 |
Elizabeth Garrett Ingram | director | 30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362 |
Thomas Gregory Moore | director | C/O AKORN, INC., 1925 WEST FIELD COURT, SUITE 300, LAKE FOREST IL 60045 |
Nishant Saxena | director | CIPLA HOUSE, PENINSULA BUSINESS PARK, LOWER PAREL, MUMBAI K7 400013 |
Jaideep Ashok Gogtay | director | CIPLA LTD., MUMBA CENTRAL, BESIDE CITY CENTER, MUMBAI K7 400008 |
From GuruFocus
By Marketwired • 08-01-2023
By Value_Insider Value_Insider • 11-10-2022
By Marketwired • 09-05-2023
By ACCESSWIRE ACCESSWIRE • 01-31-2023
By Value_Insider Value_Insider • 11-08-2022
By Marketwired • 11-02-2023
By PRNewswire PRNewswire • 01-18-2023
By GlobeNewswire GlobeNewswire • 01-27-2023
By Stock market mentor Stock market mentor • 01-27-2023
By GuruFocusNews GuruFocusNews • 11-17-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.